Its revenue growth was much above my expectation. Buy back slowly when many people are not really interested in this coma counter. It remains the cheapest pharmaceutical company in term of PER.
However, the product margin is getting higher. Pharmaceutical products usually lower margin if for generic use. But for those intensive care products will give higher profit margin. Most important thing is the growth in revenue.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
GGmalaysia
334 posts
Posted by GGmalaysia > 2016-06-18 14:24 | Report Abuse
this share is damn steady during klse sell down, means that no trader is interest in this counter = good for investor